drugset / Trial / NCT00003796

Irofulven in Treating Patients With Metastatic Breast Cancer

NCT00003796

Phase 2 Completed 32 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase II trial to study the effectiveness of irofulven in treating patients who have metastatic breast cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Timeline

Start
1999-05
Primary completion
2003-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject irofulven Small molecule Intravenous

Indications